((4S)-1-acetyl-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-proline) | 1421193-97-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ((4S)-1-acetyl-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-proline)
• CAS: 1421193-97-6
• 化学式: C₈₀H₈₉N₃₇O₁₉
• 分子量: 1872.82
• InChiKey: XAVCTMKIJLRAAI-GWKLMXKGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -8.67
• 重原子数：
  136.0
• 可旋转键数：
  24.0
• 环数：
  18.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  678.37
• 氢给体数：
  7.0
• 氢受体数：
  43.0

反应信息

• 作为产物：
  描述：

  (4S)-1-{[(9H-fluoren-9-yl)methoxy]carbonyl}-4-{4-[ (5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-proline 、 乙酸酐 在 (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate 、 N,N-二异丙基乙胺 、 哌啶 作用下， 以 N-甲基吡咯烷酮 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.05h， 生成 ((4S)-1-acetyl-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-prolyl-(4S)-4-{4-[(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl]-1H-1,2,3-triazol-1-yl}-L-proline)
  参考文献：
  名称：

  直接制备手性和构象受限的核酸肽的核酸脯氨酸氨基酸的设计与合成

  摘要：

  描述了正交保护的脯氨酸（Nup）氨基酸的直接合成及其与寡聚物的偶联。关键一步是通过Cu催化的1,3-偶极环加成反应将炔基化碱基与Fmoc保护的4-叠氮脯氨酸（Fmoc-Azp-OH）结合（点击反应）。所开发的方案允许制备> 30 g规模的脯氨酸。这些Nup氨基酸证明了固相肽合成非常简单。所得的寡核苷酸脯氨酸肽具有确定的螺旋，在H 2 O中的溶解性非常好，并且显示出与最近报道的α-核丙氨酸肽相当的细胞穿透特性。

  DOI：

  10.1002/hlca.201200557